BIOV — Biovaxys Technology Share News
0.000.00%
Last trade - 00:00- CA$3.10m
- CA$3.22m
Brief: Biovaxys Closes Final Tranche Of Non-Brokered Private Placement
Brief: Biovaxys Reports Complete Inhibition Of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein
Brief: Biovaxys Technology Corp Files Applications For International Patent And Trademark Protection Of CoviDTH
Brief: BioVaxys Files US Patent Application For Pan-Sarbecovirus Vaccine
Brief: BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission
Brief: Biovaxys Bioproduction Partner Wuxi Biologics Completes Synthesis Of Recombinant Sars-Cov-2 S-Proteins For Bvx-0320 And Covidth Programs
Brief: Biovaxys Announces Non-Brokered Private Placement Consisting Of Up To 9,090,909 Units At $0.22 Per Unit
Brief: BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development
Brief: Biovaxys Technology Files FDA Pre-Ind Meeting Request And Briefing Package For Covid-T
Brief: BioVaxys Expands Intellectual Property Portfolio
Brief: BioVaxys Enters Agreement With Inotiv For Preclinical Studies Of Its Covid-T Immunodiagnostic Program
Brief: BioVaxys Enters Agreement With Wuxi Biologics To Synthesize Proteins For Its SARS-CoV-2 Vaccine
Brief: Biovaxys And Bioelpida Sign Term Sheet For Clinical Grade Bvx-0918A Bio-Production